MedTrace Logo

A Study to Investigate the Safety and Efficacy of Ricolinostat

NCT05229042 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-12-04

No results posted yet for this study

Summary

This is a double-blind, placebo-controlled study during which patients will receive ricolinostat or placebo.

Conditions

  • Peripheral Nervous System Diseases

Interventions

DRUG

Ricolinostat

Oral

Sponsors & Collaborators

  • Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Binhe Xue · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2023-11-10
Completion
2023-11-10
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05229042 on ClinicalTrials.gov